Versant Venture Management LLC's Q4 2023 13F: 1 exit

Form 13F-HR for the quarter ended Dec 31, 2023 · filed Feb 8, 2024 · 7 reported positions · accession 0000950123-24-001156

What changed this quarter

Versant Venture Management LLC's changes in reported equity positions, Q4 2023
Activity Security Weight before Weight now Change Shares Shares %
Exited Minerva Surgical Inc. (UTRS) 0.1% — −0.1 pts −83,684 sh −100%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 100.0% of the equity book

Changes in the top 10 this quarter: UTRS left

# Security Weight before Weight now
1 RayzeBio, Inc. (RYZB) 60.9% 82.5%
2 CRISPR Therapeutics AG (CRSP) 12.0% 8.0%
3 Repare Therapeutics, Inc. (RPTX) 17.0% 5.0%
4 Gritstone Bio, Inc. (GRTS) 3.3% 1.9%
5 Passage Bio, Inc. (PASG) 1.7% 1.3%
6 Adverum Biotechnologies, Inc. (ADVM) 4.0% 1.0%
7 Aligos Therapeutics, Inc. (ALGS) 0.9% 0.4%
— Minerva Surgical Inc. (UTRS) 0.1% 0.0% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).